[Phase II study of the treatment of CML blast crisis with vindesine and prednisone].
16 patients with CML-BC were treated with vindesine/prednisone. Complete remissions were achieved in 3 cases which lasted 1 month (myeloid), 3 months (mixed) and 5 months (lymphoid). Minor responses, including less than 50% reduction of absolute blast counts and marked regression of organomegaly with a median duration of 3 weeks, occurred in 11 patients. Two patients did not respond to VDS. Leukopenia and thrombocytopenia were severe and prolonged, independent of their phenotype.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010198:Pancytopenia / Q000139:chemically induced; D011241:Prednisone / Q000008:administration & dosage* / Q000009:adverse effects; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D014751:Vindesine
D000970:Antineoplastic Agents; D014747:Vinblastine; D014751:Vindesine; D011241:Prednisone
Phase-II-Studie zur Behandlung der CML-Blastenkrise mit Vindesin und Prednison.